RxSight (RXST) Stock Price, News & Analysis

Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Key Stats

• Today's Range: $7.55 to $7.92
• 50-Day Range: $7.26 to $16.23
• 52-Week Range: $6.32 to $58.23
• Volume: 445,154 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $317.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Reduce

RxSight Stock Analysis - MarketRank™

RxSight scored higher than 67% of companies evaluated by MarketBeat, and ranked 541st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Reduce

Consensus Rating

RxSight has received a consensus rating of Reduce. The company's average rating score is 1.91, and is based on 1 buy rating, 8 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

RxSight has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RxSight is -11.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RxSight is -11.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RxSight has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.14% of the float of RxSight has been sold short.

Short Interest Ratio / Days to Cover

RxSight has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RxSight has recently decreased by 14.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RxSight does not currently pay a dividend.

Dividend Growth

RxSight does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.14% of the float of RxSight has been sold short.

Short Interest Ratio / Days to Cover

RxSight has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RxSight has recently decreased by 14.34%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.06

News Sentiment

RxSight has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 40 news articles for RxSight this week, compared to 8 articles on an average week.

Search Interest

5 people have searched for RXST on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

1 people have added RxSight to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, RxSight insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.57% of the stock of RxSight is held by insiders.

Percentage Held by Institutions

78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RXST Stock Analysis - Frequently Asked Questions

How have RXST shares performed this year?

RxSight's stock was trading at $34.38 on January 1st, 2025. Since then, RXST stock has decreased by 77.3% and is now trading at $7.81.

How were RxSight's earnings last quarter?

RxSight, Inc. (NASDAQ:RXST) released its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). RxSight's revenue for the quarter was up 28.5% compared to the same quarter last year.
Read the conference call transcript.

When did RxSight IPO?

RxSight (RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

Who are RxSight's major shareholders?

Top institutional shareholders of RxSight include Y Intercept Hong Kong Ltd (0.27%), Tempus Wealth Planning LLC (0.06%), CWM LLC (0.01%) and Bessemer Group Inc. (0.01%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Ilya Goldshleger, Julie Andrews, Bakker Juliet Tammenoms, Robert Keith Warner, Tamara Fountain, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley.
View institutional ownership trends.

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RxSight own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:RXST
• CIK: 1111485
• Web: www.rxsight.com
• Phone: 949-521-7830
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for RxSight: $17.50
• High Price Target: $65.00
• Low Price Target: $9.00
• Potential Upside/Downside: +124.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.45 million
• Net Margins: -17.90%
• Pretax Margin: -17.86%
• Return on Equity: -9.54%
• Return on Assets: -8.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.68
• Quick Ratio: 11.65

Sales & Book Value

• Annual Sales: $139.93 million
• Price / Sales: 2.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.98 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 40,640,000
• Free Float: 36,748,000
• Market Cap: $316.18 million
• Optionable: Optionable
• Beta: 1.21